Assessment of the efficacy of hemodialysis on uric acid clearance in a sub-Saharan African population at the end stage kidney disease
- PMID: 32867705
- PMCID: PMC7457757
- DOI: 10.1186/s12882-020-02037-8
Assessment of the efficacy of hemodialysis on uric acid clearance in a sub-Saharan African population at the end stage kidney disease
Abstract
Background: Uricemia dramatically rises with the stage of chronic kidney disease (CKD) and correlates with its mortality. Hemodialysis (HD) being the most used treatment at the end stage in sub-Saharan Africa, we sought to evaluate its efficacy on the clearance of uric acid (UAc) when used alone and twice per week.
Methods: A cross-sectional study of all consenting patients with CKD stage 5 recruited at random during HD sessions in a reference Centre in Cameroon from January to April 2017. We collected socio-demographic data, relevant clinical information, HD related variables, and measured serum uric acid (SUA) levels before and after the dialysis to assess the uric acid clearance. A clearance between 65 and 80% and above 80% was considered as low and good efficacy of HD respectively. Statistical analysis was performed using SPSS version 21.0. Factors associated with HD efficacy were assessed using Fisher's exact test and are presented with their odds ratios (OR) and 95% confidence levels.
Results: One hundred four patients (53 females) were included. The mean age was 49.9 ± 13.3 years. Hypertension (25%) and chronic glomerulonephritis (16%) were the main suspected etiologies of CKD. The median time on renal replacement therapy by HD was 3 years [1; 6]. The prevalence of hyperuricemia was 81.9%. The means of SUA levels were 78.8 ± 13.8 mg/L and 26.4 ± 6.6 mg/L respectively before and after dialysis. Mean SUA clearance was 66% ± 10%. The efficacy of HD on UAc was moderate in 92 (63.9%) and good in 2 (1.4%) patients. Excess weight (OR 0.4 [0.2; 0.9]) and Kt/Vurea < 1.2 (OR 0.1 [0.04; 0.2]) significantly reduces the efficacy of HD.
Conclusion: HD used alone for 2 sessions per week has a moderate efficacy on uric acid clearance in CKD. Therefore, we should improve the Kt/V (> 1.2), and combine HD to uric acid lowering drugs and diet modifications to increase its efficacy.
Keywords: Chronic Kidney Disease; hemodialysis; hyperuricemia.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Roles of peritoneal clearance and residual kidney removal in control of uric acid in patients on peritoneal dialysis.BMC Nephrol. 2020 Apr 25;21(1):148. doi: 10.1186/s12882-020-01800-1. BMC Nephrol. 2020. PMID: 32334567 Free PMC article.
-
Non-adherence to hemodialysis regimens among patients on maintenance hemodialysis in sub-Saharan Africa: an example from Cameroon.Ren Fail. 2020 Nov;42(1):1022-1028. doi: 10.1080/0886022X.2020.1826965. Ren Fail. 2020. PMID: 33028122 Free PMC article.
-
Serum uric acid levels show a 'J-shaped' association with all-cause mortality in haemodialysis patients.Nephrol Dial Transplant. 2004 Feb;19(2):457-62. doi: 10.1093/ndt/gfg563. Nephrol Dial Transplant. 2004. PMID: 14736974
-
The physiology of uric acid and the impact of end-stage kidney disease and dialysis.Semin Dial. 2019 Jan;32(1):47-57. doi: 10.1111/sdi.12735. Epub 2018 Jul 10. Semin Dial. 2019. PMID: 29989213 Review.
-
Time to target uric acid to retard CKD progression.Clin Exp Nephrol. 2017 Apr;21(2):182-192. doi: 10.1007/s10157-016-1288-2. Epub 2016 Jun 23. Clin Exp Nephrol. 2017. PMID: 27339448 Review.
Cited by
-
Urate-lowering therapy for patients with gout on hemodialysis.Int J Rheum Dis. 2022 Jul;25(7):769-774. doi: 10.1111/1756-185X.14334. Epub 2022 May 16. Int J Rheum Dis. 2022. PMID: 35570645 Free PMC article.
-
Serum Uric Acid Level as an Estimated Parameter That Predicts All-Cause Mortality in Patients with Hemodialysis.J Pers Med. 2025 Jul 11;15(7):305. doi: 10.3390/jpm15070305. J Pers Med. 2025. PMID: 40710422 Free PMC article.
-
Hyperuricemia prevalence and its risk factors in uremic patients undergoing maintenance hemodialysis.BMC Nephrol. 2025 Jan 30;26(1):46. doi: 10.1186/s12882-025-03978-8. BMC Nephrol. 2025. PMID: 39885381 Free PMC article.
-
Synthesis of Nylon 6/Modified Carbon Black Nanocomposites for Application in Uric Acid Adsorption.Materials (Basel). 2020 Nov 17;13(22):5173. doi: 10.3390/ma13225173. Materials (Basel). 2020. PMID: 33212761 Free PMC article.
-
Risk factors and management of hyperuricemia after renal transplantation.Front Surg. 2023 Jan 6;9:956213. doi: 10.3389/fsurg.2022.956213. eCollection 2022. Front Surg. 2023. PMID: 36760666 Free PMC article. Review.
References
-
- GBD 2013 Mortality and Causes of Death Collaborators Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet Lond Engl. 2015;385(9963):117–171. doi: 10.1016/S0140-6736(14)61682-2. - DOI - PMC - PubMed
-
- Chronic Kidney Disease [Internet]. World Kidney Day. Available at: http://www.worldkidneyday.org/faqs/chronic-kidney-disease/. Accessed 23 Sept 2017.
-
- Kaze FF, Meto DT, Halle M-P, Ngogang J, Kengne A-P. Prevalence and determinants of chronic kidney disease in rural and urban Cameroonians: a cross-sectional study. BMC Nephrol. 2015;16 Disponible sur. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518633/. - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous